Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product, as reported by Johnson & Johnson (JNJ) were $2.264B in the first quarter of 2023. Net trade sales were $1.191B in the U.S. and $1.072B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
- Argenx, Genmab enter collaboration agreement to develop therapeutic antibodies
- Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
- Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons